Filing Flows › Retractable Technologies (RVP) › Q2 2025
Retractable Technologies (RVP) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Retractable Technologies (RVP) reported revenue of $10.4M for the second quarter 2025 (Q2 2025), +73% from a year earlier and +26% from the quarter before. Operating margin was -49.1%, net loss $87K (0.8% of revenue).
Retractable Technologies, Q2 2025: revenue $10.4M (+73% year over year), operating margin -49.1%, net loss $87K, operating cash flow −$3.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.4M | +26% | +73% |
| Operating profit | −$5.1M | — | — |
| Net earnings | −$87K | — | — |
| Operating cash flow | −$3.7M | — | — |
What changed
Revenue was $10.4M in Q2 2025, up 73% year over year and up 26% from the previous quarter. Syringes was the largest line at 57% of revenue. EasyPoint Needles added $4.0M year over year (up 2116%), 91% of the total change. Blood Collection Products declined 9%.
Operating costs exceeded revenue by $5.1M, an operating margin of -49.1%. Total costs grew 32% against revenue growth of 73%. The fastest-growing cost line was Cost of revenue (+64%). The quarter ended with a net loss of $87K, narrower than the previous quarter's $10.5M loss. Non-operating items added $5.0M, -5890% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$3.7M. Non-cash charges added back $1.9M of depreciation and amortization. Working capital and other items used $5.5M. Capital expenditures of $332K exceeded it, leaving free cash flow of −$4.1M.
Questions
What was Retractable Technologies' revenue in the second quarter 2025?
Retractable Technologies (RVP) reported revenue of $10.4M for the second quarter 2025 (Q2 2025), +73% from a year earlier and +26% from the quarter before.
Was Retractable Technologies profitable in the second quarter 2025?
Operating loss was $5.1M (-49.1% of revenue) and net loss $87K.